matching APG-2575 oral tablets. strength: 200 mg/tablet. clinical trials

An international, multicenter, randomized, double-blind, phase 3 pivotal registrational clinical study of APG-2575 (Lisaftoclax) combined with azacitidine in elderly patients with newly diagnosed acute myeloid leukemia (GLORA-3)

This study is testing a new drug, Lisaftoclax, alongside a standard treatment (azacitidine) for older patients with newly diagnosed acute myeloid leukemia (a type of blood cancer). It aims to see if adding Lisaftoclax helps people live longer and improves other aspects of their health.